Serotoninergic activation and inhibition: effects on carbohydrate tolerance and plasma insulin and glucagon.
Glucose and arginine infusion tests were performed on 12 healthy volunteers (8 males, 4 females) before and after serotoninergic activation [oral administration of L-5-hydroxytryptophan (5-HTP-) for 6 days] and serotoninergic inhibition (oral treatment with D,L-p-chloropenylalanine for 6 days). 5-HTP treatment markedly increased urinary 5-hydroxyindoleacetic acid excretion, increased the mild hyperglycemic effect of arginine infusion, and lowered the glucose disposal rate constant. The adverse effect of serotoninergic activation on glucose tolerance is not sufficiently explained by the observed changes in insulin and glucagon secretion during the fasting state and after intravenous glucose and arginine infusions. Serotoninergic inhibition did not affect the carbohydrate tolerance of normal individuals. The results of this work supports the idea that excessive indoleamine production is probably the main cause for carbohydrate intolerance in carcinoid tumors.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000328:Adult; D001120:Arginine; D001786:Blood Glucose / Q000378:metabolism*; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D005934:Glucagon / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007328:Insulin / Q000097:blood*; D008297:Male; D012701:Serotonin / Q000378:metabolism / Q000502:physiology*
D001786:Blood Glucose; D007328:Insulin; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D005934:Glucagon; D001120:Arginine; D006916:5-Hydroxytryptophan; D010134:Fenclonine